| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.097 | 0.004 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.004 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.004 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.083 | 0.006 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.083 | 0.006 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.007 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.008 |